Clark Eliana's Form 4 filing
Intellia Therapeutics, Inc. (NTLA) · filed Mar 3, 2026
- Accession no.
- 0001193125-26-088241
- Filed
- Mar 3, 2026
- Trade date
- Mar 1-2, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $8.36K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Clark ElianaCIK 0001914448 | Officer (EVP, Chief Technical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 1, 2026 | Common Stock | AGrant or awardAcquired | +7,353 | $0.00 | $0 | 94,471 | Direct | |
| Mar 2, 2026 | Common Stock | SSaleDisposed | −607 | $13.78 | −$8,364.46 | 93,864 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 1, 2026 | Common Stock | AGrant or awardAcquired | +10,505 | $0.00 | $0 | 10,505 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.